Oral Compounds Boost Circulating Mesenchymal Stem Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for administering mesenchymal stem cells (MSCs) for therapeutic purposes face limitations, such as systemic exposure being hindered by MSCs becoming trapped in the lung when given intravenously, necessitating an alternative approach to increase circulating MSCs and treat various disorders effectively.
Innovation Solution
Administration of compounds with a specific general formula, containing five- or six-membered heteroaryl or heterocyclyl rings, which stimulate MSC proliferation and increase circulating MSCs, thereby treating a range of disorders including myocardial infraction, diabetes, and inflammatory lung disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If MSCs are administered intravenously for therapeutic purposes, then they can reach systemic circulation, but they become trapped in the lung which limits systemic exposure
Solution Approach 1:
The patent applies preliminary action by orally administering compounds (formulas 1-4) before MSC therapy to stimulate endogenous MSC proliferation and expansion in the bone marrow. This preparatory step increases the reservoir of circulating MSCs prior to any potential intravenous administration, ensuring adequate systemic exposure without relying on direct IV MSC injection that causes lung trapping
Solution Approach 2:
The patent uses small molecule compounds (formulas 1-4) as intermediaries to indirectly increase circulating MSCs. Instead of directly administering MSCs that would be trapped in the lung, these compounds act as mediators that stimulate endogenous MSC production and release into circulation, bypassing the lung trapping problem while achieving therapeutic MSC levels
2Quantity of substance
If MSCs are sourced from fetal or adult tissue and expanded in culture for therapy, then sufficient cell numbers can be obtained, but the process is complex and time-consuming
Solution Approach 1:
The patent enables the patient's own body to serve as the source of therapeutic MSCs. By orally administering compounds (formulas 1-4) that stimulate endogenous MSC proliferation in the bone marrow, the body self-generates sufficient circulating MSCs without requiring external sourcing from fetal or adult tissue and subsequent culture expansion
Solution Approach 2:
The patent changes the parameter of MSC availability from fixed (sourced from tissue) to dynamic (stimulated by oral compounds). The compounds (formulas 1-4) alter the physiological state by stimulating MSC proliferation and release, transforming the limited endogenous MSC pool into a sufficient therapeutic reservoir without complex ex vivo expansion processes
3Reliability
If MSCs are administered to treat various disorders, then therapeutic benefits can be achieved, but the method requires complex administration protocols
Solution Approach 1:
The patent replaces the mechanical/invasive method of intravenous MSC injection with an oral pharmacological approach. Instead of mechanically administering live cells that require complex handling, routing, and delivery infrastructure, the invention uses orally available small molecule compounds (formulas 1-4) that can be administered through simple oral dosage forms, substituting a complex cell delivery system with a straightforward pharmacological system
Data Source
AI summary
Disclosed herein are methods for increasing circulating mesenchymal stem cells by administering a compound having the general formula 1 as defined herein, or a pharmaceutically acceptable salt thereof.